Moleculin Biotech, Inc. financial data

Symbol
MBRX on Nasdaq
Location
Houston, TX
Fiscal year end
31 December
Latest financial report
18 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 132% % -41%
Debt-to-equity -5082% % -9672%
Return On Equity 7859% %
Return On Assets -158% % -46%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5,336,350 shares -62%
Common Stock, Shares, Outstanding 3,199,228 shares 2267%
Entity Public Float $8,800,000 USD -2.2%
Common Stock, Value, Issued $3,000 USD
Weighted Average Number of Shares Outstanding, Basic 1,184,569 shares 760%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $15,891,000 USD -10%
General and Administrative Expense $9,122,000 USD 3.8%
Operating Income (Loss) $25,103,000 USD 5.8%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $33,560,000 USD -29%
Earnings Per Share, Basic -28.42 USD/shares 85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $8,878,000 USD 108%
Assets, Current $9,686,000 USD 86%
Property, Plant and Equipment, Net $78,000 USD -51%
Operating Lease, Right-of-Use Asset $314,000 USD -26%
Other Assets, Noncurrent $900,000 USD
Assets $22,126,000 USD 31%
Accounts Payable, Current $3,508,000 USD 73%
Employee-related Liabilities, Current $1,821,000 USD 0.22%
Accrued Liabilities, Current $3,346,000 USD 0.51%
Liabilities, Current $6,854,000 USD 28%
Operating Lease, Liability, Noncurrent $222,000 USD -38%
Liabilities $7,120,000 USD 25%
Accumulated Other Comprehensive Income (Loss), Net of Tax $10,000 USD
Retained Earnings (Accumulated Deficit) $206,004,000 USD -19%
Stockholders' Equity Attributable to Parent $15,006,000 USD 34%
Liabilities and Equity $22,126,000 USD 31%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,564,000 USD 32%
Net Cash Provided by (Used in) Financing Activities $7,999,000 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 500,000,000 shares 400%
Common Stock, Shares, Issued 3,199,228 shares 2267%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $3,438,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8,878,000 USD 108%
Deferred Tax Assets, Valuation Allowance $43,669,000 USD 13%
Deferred Tax Assets, Gross $43,737,000 USD 13%
Operating Lease, Liability $359,000 USD -25%
Payments to Acquire Property, Plant, and Equipment $0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $33,509,000 USD -28%
Lessee, Operating Lease, Liability, to be Paid $407,000 USD -28%
Operating Lease, Liability, Current $137,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Two $141,000 USD -14%
Lessee, Operating Lease, Liability, to be Paid, Year One $164,000 USD 3.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.096 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $48,000 USD -45%
Lessee, Operating Lease, Liability, to be Paid, Year Three $61,000 USD -57%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $339,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $41,000 USD -33%
Operating Lease, Payments $160,000 USD 9.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $90,000 USD -29%
Deferred Tax Assets, Net of Valuation Allowance $68,000 USD -26%
Share-based Payment Arrangement, Expense $1,664,000 USD -3.6%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%